Navigation Links
Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 26, 2007 - Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today the publication* in the April 18, 2007 issue of the Journal of Neuroscience a study by researchers at the University of Colorado and National Jewish Medical and Research Center demonstrating that the Company's first orally available catalytic antioxidant, AEOL 11207, demonstrated neuroprotection in an animal model of Parkinson's disease ("PD"). The study also showed that the compound has favorable blood-brain barrier permeability.

AEOL 11207 was tested for neuroprotection and oral bio-availability in the mouse MPTP model of Parkinson's disease. AEOL 11207 administered orally protected against MPTP-induced dopamine depletion in the striatum as well as dopaminergic neuronal loss, glutathione depletion, lipid peroxidation, and 3-nitrotyrosine formation in the ventral midbrain. Neuroprotection correlated with brain metalloporphyrin concentrations. The researchers concluded that AEOL 11207 demonstrated neuroprotection in the MPTP mouse model and that the data support further investigation of AEOL 11207 as a potential treatment for PD and other neuro-degenerative diseases.

The Potential for AEOL 11207 in Parkinson's and other Neurodegenerative Diseases

A major hurdle to the treatment of chronic neurodegenerative diseases is the development of efficacious and bioavailable therapeutic agents that permeate the blood-brain barrier. Catalytic removal of reactive species is a highly warranted, yet novel approach for the treatment of age related neurodegenerative diseases such as PD. The major therapeutic approach currently used to alleviate the symptoms of PD involves restoration of dopaminergic neurotransmission using levodopa, dopamine agonists, and inhibitors of monoamine metabolism. However, these therapeutic approaches are often associated with serious adverse effects and fail to provide long-
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/19/2014)... 2014 In today,s rapidly changing, highly ... tools are essential for survival. The world is ... desires, preferences, and unmet needs are evolving rapidly. ... across all industries are continually searching for innovative ... adoption of new market research techniques like mobile ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between ... hearing health was forgotten. But Audicus , a ... hear better this new year. Hearing loss ... the aging population, though it is often unaddressed. Forty-eight ... four has a hearing aid, mainly due to price. ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Audicus Will Help People Resolve to Hear Better in 2015 2
... IntraOp Medical Corporation   (OTC: IOPD) is pleased to  ... nullification case that IntraOp Medical had appealed, and have ... IOERT linear accelerator with "straight through" accelerator guide design ... IntraOp Medical,s European Patent EP 0 700 ...
... Feb. 1, 2012 A new skin cancer drug tested ... at the Virginia G. Piper Cancer Center at Scottsdale Healthcare ... Administration, a remarkable accomplishment in new drug development. ... administered for the first time in the world Jan. 23, ...
Cached Medicine Technology:IntraOp Medical wins Patent Defense Suit Protecting Their Intellectual Property 2IntraOp Medical wins Patent Defense Suit Protecting Their Intellectual Property 3FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen 2FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen 3
(Date:12/19/2014)... Energy Textiles is excited to announce ... the world’s leading responsive textile, can now be ... are a number of benefits to wearing Celliant, ... balanced body temperature; which can lead to enhanced ... athletic performance; and overall wellness. In addition, the ...
(Date:12/19/2014)... 2014 Eufaula, Oklahoma, located just 9 ... the state’s largest lake with more than 600 miles ... to a little more than 3,000 residents, hosted its ... the 6th of December. , Featuring Santa, Christmas lights ... Eufaula on Main Street. Narconon Arrowhead’s parade float ...
(Date:12/19/2014)... December 20, 2014 The print component ... and Business subscription of the Toronto Star, with a ... of 622,169. The digital component is distributed nationally through ... of top news sites and partner outlets. To explore ... . , The publication features an exclusive interview ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Potentially illness-causing ... herbs bought at farmers markets, according to a new ... almost 50 vendors from 13 farmers markets in Los ... Seattle area. Out of almost 150 samples tested, 24 ... positive for salmonella, according to the researchers. Both ...
(Date:12/19/2014)... -- Older adults who have lost all their teeth have ... still have at least some of their teeth, a new ... could provide an early warning of increased risk of physical ... However, the findings don,t prove that tooth loss causes ... than 3,100 participants 60 and older. People with no remaining ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2
... determining factor, study finds , , TUESDAY, Jan. 22 (HealthDay ... for fast-moving prostate cancer can save lives, but the ... serious medical problems, a new study shows. , "The ... is a difference in outcome, depending on the gentleman,s ...
... pounds than dieting and exercise do, study shows , , ... gastric lap-band surgery isn,t only for the most obese; it ... , Still, the surgery is extremely expensive and carries risks. ... need alternative ways to shed pounds, said study author John ...
... MENTOR, Ohio, Jan. 22 STERIS Corporation,(NYSE: STE ... authorized a,regular quarterly dividend in the amount of $0.06 ... to shareholders of record at the close,of business on ... of STERIS Corporation is to provide a healthier today ...
... of Navarra PhD in chemistry researcher, Esther Vicente, has ... Her thesis, defended at the Faculty of Sciences in ... describes the synthesis and characterisation of 65 derivatives of ... number of antimalalarial and antituberculosis pharmaceutical drugs currently on ...
... January 22, 2007, Weinheim, DE: Wiley-Blackwell, the scientific, ... Wiley & Sons, Inc., published a comprehensive resource ... function. , Proteins are essential components of all ... and function of each cell and, ultimately, the ...
... how to manipulate the immune system to increase its ... , Published in the current edition of Viral ... new and more effective vaccines against diseases like influenza ... , The study suggests that scientists can boost the ...
Cached Medicine News:Health News:Hormone Therapy Only Helps Some Older Men With Prostate Cancer 2Health News:Gastric Lap-Band Surgery Can Send Diabetes Into Remission 2Health News:Gastric Lap-Band Surgery Can Send Diabetes Into Remission 3Health News:STERIS Corporation Declares Regular Quarterly Dividend 2Health News:STERIS Corporation Declares Regular Quarterly Dividend 3Health News:Research discovers new compounds active against tuberculosis and malaria 2Health News:'The Handbook of Proteins' 2